Aurobindo Pharma (AUROPHARMA) Q4 24/25 earnings summary

Executive summary

• Achieved record revenues and EBITDA for FY 2025, with strong growth across all business segments, especially in regulated markets and through new product launches.

• Consolidated revenue from operations for FY25 was ₹317,237.3 million, up from ₹290,018.7 million in FY24, reflecting strong year-over-year growth.

• Net profit after tax for FY25 stood at ₹34,835.7 million, compared to ₹31,689.7 million in FY24.

• Net cash position improved to $42 million from a net debt of $84 million at the end of December 2024, reflecting better working capital management.

• Significant progress in biosimilars with multiple regulatory approvals and pipeline advancements.

Financial highlights

• FY 2025 revenue: INR 31,724 crore (up 9% YoY); Q4 revenue: INR 8,382 crore (up 11% YoY, 5% QoQ).

• FY 2025 EBITDA: INR 6,605 crore (margin 20.8%); Q4 EBITDA: INR 1,792 crore (margin 21.4%).

• Q4 net profit: INR 903 crore (up 7% QoQ).

• Gross margin for FY 2025: 58.9% (up 214 bps YoY); Q4 gross margin: 59.1% (up 65 bps QoQ).

• R&D expenditure: INR 1,622 crore for FY 2025 (5.1% of revenue).

Outlook and guidance

• Targeting high single-digit revenue growth (excluding transient products) and maintaining current EBITDA margins for FY 2026.

• Growth momentum expected to continue in Europe and key markets; U.S. business to remain stable with muted growth in FY 2026, stronger in FY 2027.

• First supplies of four biosimilars to EU markets expected by Q3/Q4 FY26.

• Multiple biosimilar regulatory submissions planned in FY26, including first US FDA submission.

• Tariff announcements in July 2025 may impact outlook; further clarity to be provided in the next earnings call.